- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03855189
Safety and Efficacy of Mometasone Furoate (SCH 032088) vs Beclomethasone Dipropionate or Placebo in Seasonal Allergic Rhinitis (C93-013)
February 7, 2022 updated by: Organon and Co
Safety and Efficacy of SCH 32088 vs Beclomethasone Dipropionate (Vancenase AQ) and Placebo in Seasonal Allergic Rhinitis
The objectives of this study are to determine the safety and efficacy in seasonal allergic rhinitis of a four-week course of mometasone furoate compared to beclomethasone dipropionate or placebo.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
345
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
10 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Nonpregnant women of childbearing potential must be using a medically acceptable form of birth control for at least 3 months prior to Screening, and must continue its use for the duration of the study. Women not of childbearing potential must be surgically sterilized or at least one year post menopausal, or be otherwise incapable of bearing children
- 2-year history of seasonal allergic rhinitis
- Positive skin test response to a local seasonal allergen within last 2 years
- Good health and free of any unstable, clinically significant disease, other than allergic rhinitis, that would interfere with the study schedule or evaluation of seasonal allergic rhinitis
Exclusion Criteria:
- Women who are pregnant or breastfeeding
- Women of childbearing potential who are not using an acceptable form of birth control
- Pre-menarchal females
- Asthma requiring therapy with inhaled or systemic corticosteroids
- Significant renal, hepatic, neurologic, cardiovascular, hematologic, metabolic, cerebrovascular, respiratory, gastrointestinal, or other significant medical illness or disorder which, in the judgment of the investigator, may interfere with the study, or require treatment which might interfere with the study
- On immunotherapy (unless maintenance therapy)
- Upper respiratory tract or sinus infection that requires antibiotic therapy within the previous 2 weeks
- Use of any investigational drug within the previous 90 days unless the investigational drug is a nasal corticosteroid or has a short (12 hours or less) duration of action, in which case the washout period will be 30 days
- Large nasal polyps, marked septal deviations or any other nasal structural abnormality that significantly interferes with nasal air flow
- Allergy to corticosteroids, or a history of multiple drug allergies
- History of posterior subcapsular cataracts
- Dependence upon nasal, oral or ocular decongestants or who are diagnosed with rhinitis medicamentosa
- Chronic use of any medication which could affect the course of seasonal allergic rhinitis
- Clinically significant abnormal electrocardiogram (ECG)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mometasone Furoate (MF)
Participants receive 200 mcg nasal MF in the morning upon awakening and placebo approximately 12 hours later in the evening (200 mcg total daily dose) for 29 days.
|
Mometasone furoate nasal spray administered as 200 mcg total dose per day for 4 weeks.
Other Names:
Placebo nasal spray administered for 4 weeks.
|
Active Comparator: Beclomethasone Dipropionate (BDP)
Participants receive 168 mcg nasal BDP in the morning upon awakening and an additional 168 mcg approximately 12 hours later in the evening (336 mcg total daily dose) for 29 days.
|
Beclomethasone dipropionate nasal spray administered as 168 mcg twice daily (BID) [336 mcg total dose per day] for 4 weeks.
Other Names:
|
Placebo Comparator: Placebo
Participants receive nasal placebo in the morning upon awakening and again approximately 12 hours later in the evening for 29 days.
|
Placebo nasal spray administered for 4 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in the Total Nasal Symptom Score (TNSS) (Average of Morning [AM]/Evening [PM] Score) Averaged Over Days 1 to 15 (Participant-Evaluated)
Time Frame: Baseline, and Days 1 through 15 (average of 15 days of treatment)
|
TNSS evaluated participant nasal symptoms of discharge (rhinorrhea), stuffiness, sneezing, and itching, as rated in their diary in the morning (AM) and evening (PM).
The 4 individual symptom scores rated as follows: 0 = none, 1 = mild, 2 = moderate, 3 = severe.
TNSS was the sum of the 4 individual symptom scores (range= 0-12, higher score indicating more frequent/severe nasal symptoms).
For the 15 day interval, participant individual daily scores were totaled and averaged over interval (AM and PM computed separately then averaged) and used to calculate the overall average change from Baseline.
Participant average changes were then used to calculate the mean change for each arm for the interval.
Average change from Baseline for Days 1-15 = average post-treatment score (Days 1-15) - Baseline average score (average of the Baseline AM/PM diary scores from 3 consecutive days prior to Baseline visit).
Negative changes from baseline indicate a decrease in symptom severity.
|
Baseline, and Days 1 through 15 (average of 15 days of treatment)
|
Number of Participants Who Experienced ≥1 Adverse Event
Time Frame: Up to 31 Days
|
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment.
An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure.
Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE.
The number of participants with at least one AE was reported for each treatment group.
|
Up to 31 Days
|
Number of Participants Who Discontinued Treatment Due to An Adverse Event (AE)
Time Frame: Up to 31 Days
|
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment.
An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure.
Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE.
The number of participants who discontinued due to an AE was reported for each treatment group.
|
Up to 31 Days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in the TNSS At Day 4 (Physician-Evaluated)
Time Frame: Baseline (Day 1), Day 4
|
TNSS evaluated participant nasal symptoms of discharge (rhinorrhea), stuffiness, sneezing, and itching.
The 4 individual symptom scores were rated by the physician at the visit as follows: 0 = none, 1 = mild, 2 = moderate, 3 = severe.
TNSS was the sum of the 4 individual symptom scores (range= 0-12, higher score indicating more frequent/severe nasal symptoms).
For each participant, individual scores were totaled and used to calculate the change from Baseline in TNSS at the visit.
Participant changes were then used to calculate the mean change for each treatment group at that visit.
Change from Baseline = visit score - Baseline score (Day 1 visit).
Negative changes from baseline indicate a decrease in symptom severity.
|
Baseline (Day 1), Day 4
|
Change From Baseline in the TNSS At Day 8 (Physician-Evaluated)
Time Frame: Baseline (Day 1), Day 8
|
TNSS evaluated participant nasal symptoms of discharge (rhinorrhea), stuffiness, sneezing, and itching.
The 4 individual symptom scores were rated by the physician at the visit as follows: 0 = none, 1 = mild, 2 = moderate, 3 = severe.
TNSS was the sum of the 4 individual symptom scores (range= 0-12, higher score indicating more frequent/severe nasal symptoms).
For each participant, individual scores were totaled and used to calculate the change from Baseline in TNSS at the visit.
Participant changes were then used to calculate the mean change for each treatment group at that visit.
Change from Baseline = visit score - Baseline score (Day 1 visit).
Negative changes from baseline indicate a decrease in symptom severity.
|
Baseline (Day 1), Day 8
|
Change From Baseline in the TNSS At Day 15 (Physician-Evaluated)
Time Frame: Baseline (Day 1), Day 15
|
TNSS evaluated participant nasal symptoms of discharge (rhinorrhea), stuffiness, sneezing, and itching.
The 4 individual symptom scores were rated by the physician at the visit as follows: 0 = none, 1 = mild, 2 = moderate, 3 = severe.
TNSS was the sum of the 4 individual symptom scores (range= 0-12, higher score indicating more frequent/severe nasal symptoms).
For each participant, individual scores were totaled and used to calculate the change from Baseline in TNSS at the visit.
Participant changes were then used to calculate the mean change for each treatment group at that visit.
Change from Baseline = visit score - Baseline score (Day 1 visit).
Negative changes from baseline indicate a decrease in symptom severity.
|
Baseline (Day 1), Day 15
|
Change From Baseline in the TNSS At Day 22 (Physician-Evaluated)
Time Frame: Baseline (Day 1), Day 22
|
TNSS evaluated participant nasal symptoms of discharge (rhinorrhea), stuffiness, sneezing, and itching.
The 4 individual symptom scores were rated by the physician at the visit as follows: 0 = none, 1 = mild, 2 = moderate, 3 = severe.
TNSS was the sum of the 4 individual symptom scores (range= 0-12, higher score indicating more frequent/severe nasal symptoms).
For each participant, individual scores were totaled and used to calculate the change from Baseline in TNSS at the visit.
Participant changes were then used to calculate the mean change for each treatment group at that visit.
Change from Baseline = visit score - Baseline score (Day 1 visit).
Negative changes from baseline indicate a decrease in symptom severity.
|
Baseline (Day 1), Day 22
|
Change From Baseline in the TNSS At Day 29 (Physician-Evaluated)
Time Frame: Baseline (Day 1), Day 29
|
TNSS evaluated participant nasal symptoms of discharge (rhinorrhea), stuffiness, sneezing, and itching.
The 4 individual symptom scores were rated by the physician at the visit as follows: 0 = none, 1 = mild, 2 = moderate, 3 = severe.
TNSS was the sum of the 4 individual symptom scores (range= 0-12, higher score indicating more frequent/severe nasal symptoms).
For each participant, individual scores were totaled and used to calculate the change from Baseline in TNSS at the visit.
Participant changes were then used to calculate the mean change for each treatment group at that visit.
Change from Baseline = visit score - Baseline score (Day 1 visit).
Negative changes from baseline indicate a decrease in symptom severity.
|
Baseline (Day 1), Day 29
|
Change From Baseline in Overall Condition of Seasonal Allergic Rhinitis At Day 4 (Physician-Evaluated)
Time Frame: Baseline (Day 1), Day 4
|
Overall condition of seasonal allergic rhinitis was evaluated by the physician during the visit and scored on a scale from 0 to 3 as follows: 0 = none, 1 = mild, 2 = moderate, 3 = severe.
A higher score indicated more frequent/severe nasal symptoms.
Change from Baseline = visit score - Baseline score (Day 1 visit).
Negative changes from baseline indicate a decrease in symptom severity.
|
Baseline (Day 1), Day 4
|
Change From Baseline in Overall Condition of Seasonal Allergic Rhinitis At Day 8 (Physician-Evaluated)
Time Frame: Baseline (Day 1), Day 8
|
Overall condition of seasonal allergic rhinitis was evaluated by the physician during the visit and scored on a scale from 0 to 3 as follows: 0 = none, 1 = mild, 2 = moderate, 3 = severe.
A higher score indicated more frequent/severe nasal symptoms.
Change from Baseline = visit score - Baseline score (Day 1 visit).
Negative changes from baseline indicate a decrease in symptom severity.
|
Baseline (Day 1), Day 8
|
Change From Baseline in Overall Condition of Seasonal Allergic Rhinitis At Day 15 (Physician-Evaluated)
Time Frame: Baseline (Day 1), Day 15
|
Overall condition of seasonal allergic rhinitis was evaluated by the physician during the visit and scored on a scale from 0 to 3 as follows: 0 = none, 1 = mild, 2 = moderate, 3 = severe.
A higher score indicated more frequent/severe nasal symptoms.
Change from Baseline = visit score - Baseline score (Day 1 visit).
Negative changes from baseline indicate a decrease in symptom severity.
|
Baseline (Day 1), Day 15
|
Change From Baseline in Overall Condition of Seasonal Allergic Rhinitis At Day 22 (Physician-Evaluated)
Time Frame: Baseline (Day 1), Day 22
|
Overall condition of seasonal allergic rhinitis was evaluated by the physician during the visit and scored on a scale from 0 to 3 as follows: 0 = none, 1 = mild, 2 = moderate, 3 = severe.
A higher score indicated more frequent/severe nasal symptoms.
Change from Baseline = visit score - Baseline score (Day 1 visit).
Negative changes from baseline indicate a decrease in symptom severity.
|
Baseline (Day 1), Day 22
|
Change From Baseline in Overall Condition of Seasonal Allergic Rhinitis At Day 29 (Physician-Evaluated)
Time Frame: Baseline (Day 1), Day 29
|
Overall condition of seasonal allergic rhinitis was evaluated by the physician during the visit and scored on a scale from 0 to 3 as follows: 0 = none, 1 = mild, 2 = moderate, 3 = severe.
A higher score indicated more frequent/severe nasal symptoms.
Change from Baseline = visit score - Baseline score (Day 1 visit).
Negative changes from baseline indicate a decrease in symptom severity.
|
Baseline (Day 1), Day 29
|
Change From Baseline in Overall Condition of Seasonal Allergic Rhinitis At Day 4 (Participant-Evaluated)
Time Frame: Baseline (Day 1), Day 4
|
Overall condition of seasonal allergic rhinitis was evaluated by the participant during the visit and scored on a scale from 0 to 3 as follows: 0 = none, 1 = mild, 2 = moderate, 3 = severe.
A higher score indicated more frequent/severe nasal symptoms.
Change from Baseline = visit score - Baseline score (Day 1 visit).
Negative changes from baseline indicate a decrease in symptom severity.
|
Baseline (Day 1), Day 4
|
Change From Baseline in Overall Condition of Seasonal Allergic Rhinitis At Day 8 (Participant-Evaluated)
Time Frame: Baseline (Day 1), Day 8
|
Overall condition of seasonal allergic rhinitis was evaluated by the participant during the visit and scored on a scale from 0 to 3 as follows: 0 = none, 1 = mild, 2 = moderate, 3 = severe.
A higher score indicated more frequent/severe nasal symptoms.
Change from Baseline = visit score - Baseline score (Day 1 visit).
Negative changes from baseline indicate a decrease in symptom severity.
|
Baseline (Day 1), Day 8
|
Change From Baseline in Overall Condition of Seasonal Allergic Rhinitis At Day 15 (Participant-Evaluated)
Time Frame: Baseline (Day 1), Day 15
|
Overall condition of seasonal allergic rhinitis was evaluated by the participant during the visit and scored on a scale from 0 to 3 as follows: 0 = none, 1 = mild, 2 = moderate, 3 = severe.
A higher score indicated more frequent/severe nasal symptoms.
Change from Baseline = visit score - Baseline score (Day 1 visit).
Negative changes from baseline indicate a decrease in symptom severity.
|
Baseline (Day 1), Day 15
|
Change From Baseline in Overall Condition of Seasonal Allergic Rhinitis At Day 22 (Participant-Evaluated)
Time Frame: Baseline (Day 1), Day 22
|
Overall condition of seasonal allergic rhinitis was evaluated by the participant during the visit and scored on a scale from 0 to 3 as follows: 0 = none, 1 = mild, 2 = moderate, 3 = severe.
A higher score indicated more frequent/severe nasal symptoms.
Change from Baseline = visit score - Baseline score (Day 1 visit).
Negative changes from baseline indicate a decrease in symptom severity.
|
Baseline (Day 1), Day 22
|
Change From Baseline in Overall Condition of Seasonal Allergic Rhinitis At Day 29 (Participant-Evaluated)
Time Frame: Baseline (Day 1), Day 29
|
Overall condition of seasonal allergic rhinitis was evaluated by the participant during the visit and scored on a scale from 0 to 3 as follows: 0 = none, 1 = mild, 2 = moderate, 3 = severe.
A higher score indicated more frequent/severe nasal symptoms.
Change from Baseline = visit score - Baseline score (Day 1 visit).
Negative changes from baseline indicate a decrease in symptom severity.
|
Baseline (Day 1), Day 29
|
Response To Therapy At Day 4 (Physician-Evaluated)
Time Frame: Day 4
|
Response to therapy was evaluated by the physician and based upon the participant's status scored relative to Baseline.
Response was scored on a scale from 1 to 5 as follows: 1 = Complete Relief, 2 = Marked Relief, 3 = Moderate Relief, 4= Slight Relief, and 5 = Treatment Failure.
A higher score indicated a weaker response.
|
Day 4
|
Response To Therapy At Day 8 (Physician-Evaluated)
Time Frame: Day 8
|
Response to therapy was evaluated by the physician and based upon the participant's status scored relative to Baseline.
Response was scored on a scale from 1 to 5 as follows: 1 = Complete Relief, 2 = Marked Relief, 3 = Moderate Relief, 4= Slight Relief, and 5 = Treatment Failure.
A higher score indicated a weaker response.
|
Day 8
|
Response To Therapy At Day 15 (Physician-Evaluated)
Time Frame: Day 15
|
Response to therapy was evaluated by the physician and based upon the participant's status scored relative to Baseline.
Response was scored on a scale from 1 to 5 as follows: 1 = Complete Relief, 2 = Marked Relief, 3 = Moderate Relief, 4= Slight Relief, and 5 = Treatment Failure.
A higher score indicated a weaker response.
|
Day 15
|
Response To Therapy At Day 22 (Physician-Evaluated)
Time Frame: Day 22
|
Response to therapy was evaluated by the physician and based upon the participant's status scored relative to Baseline.
Response was scored on a scale from 1 to 5 as follows: 1 = Complete Relief, 2 = Marked Relief, 3 = Moderate Relief, 4= Slight Relief, and 5 = Treatment Failure.
A higher score indicated a weaker response.
|
Day 22
|
Response To Therapy At Day 29 (Physician-Evaluated)
Time Frame: Day 29
|
Response to therapy was evaluated by the physician and based upon the participant's status scored relative to Baseline.
Response was scored on a scale from 1 to 5 as follows: 1 = Complete Relief, 2 = Marked Relief, 3 = Moderate Relief, 4= Slight Relief, and 5 = Treatment Failure.
A higher score indicated a weaker response.
|
Day 29
|
Response To Therapy At Day 4 (Participant-Evaluated)
Time Frame: Day 4
|
Response to therapy was evaluated by the participant and based upon their status scored relative to Baseline.
Response was scored on a scale from 1 to 5 as follows: 1 = Complete Relief, 2 = Marked Relief, 3 = Moderate Relief, 4= Slight Relief, and 5 = Treatment Failure.
A higher score indicated a weaker response.
|
Day 4
|
Response To Therapy At Day 8 (Participant-Evaluated)
Time Frame: Day 8
|
Response to therapy was evaluated by the participant and based upon their status scored relative to Baseline.
Response was scored on a scale from 1 to 5 as follows: 1 = Complete Relief, 2 = Marked Relief, 3 = Moderate Relief, 4= Slight Relief, and 5 = Treatment Failure.
A higher score indicated a weaker response.
|
Day 8
|
Response To Therapy At Day 15 (Participant-Evaluated)
Time Frame: Day 15
|
Response to therapy was evaluated by the participant and based upon their status scored relative to Baseline.
Response was scored on a scale from 1 to 5 as follows: 1 = Complete Relief, 2 = Marked Relief, 3 = Moderate Relief, 4= Slight Relief, and 5 = Treatment Failure.
A higher score indicated a weaker response.
|
Day 15
|
Response To Therapy At Day 22 (Participant-Evaluated)
Time Frame: Day 22
|
Response to therapy was evaluated by the participant and based upon their status scored relative to Baseline.
Response was scored on a scale from 1 to 5 as follows: 1 = Complete Relief, 2 = Marked Relief, 3 = Moderate Relief, 4= Slight Relief, and 5 = Treatment Failure.
A higher score indicated a weaker response.
|
Day 22
|
Response To Therapy At Day 29 (Participant-Evaluated)
Time Frame: Day 29
|
Response to therapy was evaluated by the participant and based upon their status scored relative to Baseline.
Response was scored on a scale from 1 to 5 as follows: 1 = Complete Relief, 2 = Marked Relief, 3 = Moderate Relief, 4= Slight Relief, and 5 = Treatment Failure.
A higher score indicated a weaker response.
|
Day 29
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 23, 1993
Primary Completion (Actual)
October 8, 1993
Study Completion (Actual)
October 22, 1993
Study Registration Dates
First Submitted
February 25, 2019
First Submitted That Met QC Criteria
February 25, 2019
First Posted (Actual)
February 26, 2019
Study Record Updates
Last Update Posted (Actual)
February 9, 2022
Last Update Submitted That Met QC Criteria
February 7, 2022
Last Verified
February 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Immune System Diseases
- Hypersensitivity, Immediate
- Otorhinolaryngologic Diseases
- Respiratory Hypersensitivity
- Hypersensitivity
- Nose Diseases
- Rhinitis
- Rhinitis, Allergic
- Rhinitis, Allergic, Seasonal
- Physiological Effects of Drugs
- Anti-Inflammatory Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Dermatologic Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Anti-Allergic Agents
- Beclomethasone
- Mometasone Furoate
Other Study ID Numbers
- C93-013 (Other Identifier: Merck)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Seasonal Allergic Rhinitis
-
Glenmark Specialty S.A.CompletedSeasonal Allergic Rhinitis (SAR)United States
-
UCB PharmaCompleted
-
UCB PharmaCompletedRhinitis | Allergic | Seasonal
-
SanofiCompleted
-
Glenmark Specialty S.A.CompletedSeasonal Allergic Rhinitis (SAR)United States
-
SanofiCompleted
-
BayerCompletedRhinitis | Seasonal Rhinitis
-
GlaxoSmithKlineCompletedRhinitis, Allergic, Perennial and SeasonalUnited States
-
University of East AngliaNorfolk and Norwich University Hospitals NHS Foundation Trust; Quadram Institute... and other collaboratorsCompletedAsthma | Grass Allergy | Seasonal Affective RhinitisUnited Kingdom
-
ALK-Abelló A/SCompletedPerennial Allergic Rhinitis | Seasonal Allergic Rhinitis
Clinical Trials on Mometasone Furoate (MF)
-
Organon and CoCompleted
-
Novartis PharmaceuticalsCompletedMild AsthmaGermany, India, Korea, Republic of, Poland, South Africa, Estonia, Italy, Russian Federation, Thailand, Latvia, Lithuania, Colombia, Hungary, Peru, Philippines, Slovakia, Bulgaria, Vietnam, Japan, Malaysia, Chile, Sweden
-
Organon and CoCompleted
-
Novartis PharmaceuticalsCompleted
-
Organon and CoCompleted
-
Teva Pharmaceuticals USACompletedSeasonal Allergic Rhinitis
-
Organon and CoNovartisCompleted
-
Organon and CoNovartisCompletedChronic Obstructive Pulmonary Disease (COPD)